Relay Therapeutics Advances Zovegalisib Triplet to Phase 3 for Frontline Breast Cancer with Promising Clinical Data
Summary
Relay Therapeutics reported positive Phase 1/2 clinical data for its zovegalisib triplet combination and announced plans to advance it into a Phase 3 trial for frontline metastatic breast cancer, supported by a drug supply agreement with Pfizer.
Key Events
-
Positive Phase 1/2 Clinical Data for Zovegalisib Triplet
The zovegalisib, atirmociclib, and fulvestrant triplet achieved a 44% objective response rate (ORR) in heavily pre-treated (median third-line) PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients, with a manageable 40% Grade 3+ treatment-related adverse event (TRAE) rate.
-
Advancement to Frontline Phase 3 Development
Based on the promising data, Relay Therapeutics plans to initiate a randomized Phase 3 trial evaluating the zovegalisib plus atirmociclib and aromatase inhibitor (AI) triplet in frontline endocrine-sensitive patients, targeting a significant market.
-
Pfizer Collaboration for Drug Supply
Pfizer, Inc. has agreed to supply atirmociclib for the experimental arm and palbociclib for the control arm of the planned Phase 3 trial, with Relay Therapeutics sponsoring and funding the study.
-
Strategic Pipeline Progress
This clinical milestone for zovegalisib, which previously received Breakthrough Therapy Designation, reinforces the company's pipeline strength and follows a recent 10-K filing indicating an extended cash runway into 2029.
Analysis
Relay Therapeutics announced compelling Phase 1/2 clinical data for its zovegalisib plus atirmociclib triplet combination in heavily pre-treated metastatic breast cancer patients. The 44% objective response rate (ORR) in these median third-line patients, coupled with a manageable safety profile (40% Grade 3+ TRAEs), is a strong signal, approaching the ORR of current standard of care doublets in frontline (1L) patients. This positive data supports the company's decision to advance the triplet into a Phase 3 trial for 1L PI3Kα-mutated, HR+/HER2- metastatic breast cancer, a substantial market opportunity. The collaboration with Pfizer for drug supply further de-risks the Phase 3 execution. This development significantly strengthens the investment thesis for Relay Therapeutics' lead asset, building on the previously announced Breakthrough Therapy Designation and extended cash runway into 2029.
At the time of this filing, RLAY was trading at $15.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $2.67 to $17.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.